Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495230 | 1.00 | CA1 (0.62) | CA1CA2CA4CA9POLB | |
| SCHEMBL4749948 | 1.00 | CA1 (0.62) | CA1CA2CA4CA9POLB | |
| SCHEMBL19049072 | 0.88 | CA1 (0.60) | CA1CA2CA4CA9POLB | |
| SCHEMBL3492392 | 0.88 | CA1 (0.51) | CA1CA2CA4CA9POLB | |
| SCHEMBL19002804 | 0.86 | CA1 (0.58) | CA1CA2CA4CA9POLB | |
| SCHEMBL4973057 | 0.85 | CA1 (0.48) | CA1CA2CA4CA9PARP1 | |
| SCHEMBL18997562 | 0.85 | CA1 (0.57) | CA1CA2CA4CA9POLB | |
| SCHEMBL3493739 | 0.85 | CA1 (0.48) | CA1CA2CA4CA9PARP1 | |
| SCHEMBL18935848 | 0.85 | CA1 (0.57) | CA1CA2CA4CA9POLB | |
| SCHEMBL3494434 | 0.83 | CA1 (0.73) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-113874080-A | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3921038-A1 | IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-1408986-A4 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1408986-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | CA1 3906/4885CA2 4622/4885CA4 4496/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | CA1 3906/4885CA2 4622/4885CA4 4496/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | CA1 4137/4885CA2 632/4885CA4 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.